Scientific Focus
The program is designed to support basic and clinical research in the field of Oncology Solid Tumors in Asia, Latin America and the Middle East. For the 2025 cycle, the program will focus on Breast and Lung cancer.
Areas of research may include, but are not limited to:
Areas of research
- Disparities and inequities in cancer care
- Agnostic approaches to target solid tumors
- Combinational drug strategies/approaches to treatment
- Resistance mechanism identification/novel approaches to addressing resistance mechanisms
- Transformative, therapeutic modalities/approaches to treatment
- Patient-specific factors that are predictors of toxicity
- Genomic polymorphisms and impact treatment response
- Novel targets and/or biomarkers/imaging techniques
- Novel diagnostic, prevention, and treatment strategies
- Research to improve Quality of Life (QoL) Patient-Reported Outcomes (PRO's) e.g adverse events, addressing unmet needs for patients
- Any other pre-clinical or clinical research that addresses an unmet medical need or gap in scientific knowledge
Requirements
Gilead Affiliated Products
Funding Ineligibility
Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.
Gilead Internal Validation
The Research Scholars Program is intended to support independent research by emerging investigators that is unrelated to Gilead’s strategies or priorities. However, all research projects selected by the Scientific Review Committee will need to be approved by an internal validation committee that, in rare circumstances, may be unable to support certain clinical interventional studies (e.g., studies focused solely on the safety and/or efficacy of non-Gilead products).
Proposal Review
Proposals are reviewed by an independent Scientific Review Committee, (no Commercial involvement in review or selection, i.e., Marketing, Sales, and Commercial Strategy), and are reviewed based upon the criteria outlined on this website.
Top FAQs
The award is an industry sponsored award funded by Gilead Sciences, Inc. which is a for profit entity, not the Gilead Foundation. While the award is funded by Gilead Sciences, Inc., the review of the applications and selection of awardees is carried out by an independent scientific review committee. Gilead is not part of the scientific review committee and has no involvement in selecting the applications that receive the awards.
The approximate protected time refers to time spent on research in general. This time does not need to be spent only on research related to your RSP proposal.
The approximate protected time refers to time spent on research in general. This time does not need to be spent only on research related to your RSP proposal.
